Sunshine Biopharma Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sunshine Biopharma Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.31M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $34.87M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $24.09M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $4.35M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $228.4K | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $71.4K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $21.1K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 12, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.26M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $10.67M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $8.34M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $1.70M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $110.6K | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $45.6K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $10.1K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 12, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.98M) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($5.13M) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($4.51M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($26.74M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($12.44M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($2.78M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($1.66M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.16M) | May 1, 2020 |
| FY2018 | Dec 31, 2017 | ($1.04M) | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | ($3.50M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.23M) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($5.81M) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($4.79M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($27.00M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.44M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($576.9K) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($641.6K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.16M) | May 1, 2020 |
| FY2018 | Dec 31, 2017 | ($857.2K) | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | ($993.1K) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $604.3K | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $933.9K | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $1.86M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $811.9K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $672.2K | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $1.7K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $15.2K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $12.8K | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | $32.8K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.33M) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($12.52M) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($8.78M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($5.25M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.83M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($657.3K) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($495.8K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($512.8K) | May 1, 2020 |
| FY2018 | Dec 31, 2017 | ($543.5K) | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | ($314.2K) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $174.5K | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $1.66M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $82.3K | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $194.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $1.2K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $860 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $18.9K | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $3.7K | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | $3.4K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.08M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $30.56M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $27.35M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $29.24M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.20M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $1.05M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $98.1K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.15M | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $257.5K | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | $64.4K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.04M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $7.06M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $6.14M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $7.62M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.99M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $2.00M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $833.5K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.20M | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $830.8K | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | $274.1K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.04M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $23.50M | Apr 3, 2026 |
| FY2025 | Dec 31, 2023 | $21.21M | Apr 3, 2026 |
| FY2024 | Dec 31, 2022 | $21.63M | Apr 1, 2025 |
| FY2023 | Dec 31, 2021 | $211.7K | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($954.8K) | Apr 4, 2023 |
| FY2021 | Dec 31, 2019 | ($735.4K) | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | ($55.8K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($573.4K) | May 1, 2020 |
| FY2018 | Dec 31, 2016 | ($209.7K) | Apr 12, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 1, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 1, 2025 |
| FY2024 | Dec 31, 2022 | $0 | Apr 1, 2025 |
| FY2024 | Dec 31, 2021 | $0 | Apr 1, 2025 |
| FY2020 | Dec 31, 2019 | $665.7K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $665.7K | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.02M) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($69.04M) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($63.91M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($59.40M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($32.66M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($20.22M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($17.43M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($15.77M) | May 1, 2020 |
| FY2018 | Dec 31, 2017 | ($13.62M) | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | ($12.58M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $21.83M | Apr 4, 2023 |
| FY2022 | Dec 31, 2021 | $2.05M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $989.9K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $40.5K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $110.5K | May 1, 2020 |
| FY2018 | Dec 31, 2017 | $107.5K | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | $57.5K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $50.8K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $143.4K | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | $31.2K | Mar 11, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | (351) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | May 1, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (7) | Apr 1, 2025 |
| FY2024 | Dec 31, 2023 | (351) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Apr 4, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.91M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | 2.58M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | 14,012 | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 22.59M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 2.59M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | 1.73M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 35.32M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 4.28M | May 1, 2020 |
| FY2018 | Dec 31, 2017 | 45.94M | Apr 12, 2019 |
| FY2017 | Dec 31, 2016 | 769.40M | Apr 2, 2018 |